Trevi Therapeutics (TRVI) Enterprise Value (2018 - 2026)

Trevi Therapeutics' Enterprise Value history runs 9 years deep, the most recent figure standing at -$171.8 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 66.36% year-over-year to -$171.8 million in Q1 2026; TTM through Mar 2026 was -$171.8 million, a 66.36% decrease from a year earlier, with the FY2025 full-year figure at -$188.3 million, down 74.93% from the prior year.
• Enterprise Value grew to -$171.8 million in Q1 2026 per TRVI's latest filing, from -$188.3 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$42.3 million in Q1 2022 and bottomed at -$203.9 million in Q2 2025.
• The 5-year median for Enterprise Value is -$103.3 million (2025), against an average of -$113.0 million.
• Across the five-year window, Enterprise Value slumped 328.42% in 2022 and soared 34.55% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$120.5 million in 2022, then surged by 31.15% to -$83.0 million in 2023, then fell by 29.71% to -$107.6 million in 2024, then slumped by 74.93% to -$188.3 million in 2025, then grew by 8.75% to -$171.8 million in 2026.
• Per Business Quant, the three latest TRVI Enterprise Value figures stand at -$171.8 million (Q1 2026), -$188.3 million (Q4 2025), and -$194.9 million (Q3 2025).